- Home
- ZION vs RVMD Comparison
ZION vs RVMD Comparison
Compare ZION & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZION
- RVMD
- Stock Information
- Founded
- ZION 1873
- RVMD 2014
- Country
- ZION United States
- RVMD United States
- Employees
- ZION N/A
- RVMD N/A
- Industry
- ZION Major Banks
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZION Finance
- RVMD Health Care
- Exchange
- ZION Nasdaq
- RVMD Nasdaq
- Market Cap
- ZION 7.2B
- RVMD 7.5B
- IPO Year
- ZION N/A
- RVMD 2020
- Fundamental
- Price
- ZION $56.37
- RVMD $38.11
- Analyst Decision
- ZION Hold
- RVMD Strong Buy
- Analyst Count
- ZION 21
- RVMD 12
- Target Price
- ZION $56.85
- RVMD $68.67
- AVG Volume (30 Days)
- ZION 1.3M
- RVMD 3.3M
- Earning Date
- ZION 07-21-2025
- RVMD 08-06-2025
- Dividend Yield
- ZION 3.06%
- RVMD N/A
- EPS Growth
- ZION 28.66
- RVMD N/A
- EPS
- ZION 5.12
- RVMD N/A
- Revenue
- ZION $3,106,000,000.00
- RVMD N/A
- Revenue This Year
- ZION $9.03
- RVMD N/A
- Revenue Next Year
- ZION $4.02
- RVMD $241.39
- P/E Ratio
- ZION $10.98
- RVMD N/A
- Revenue Growth
- ZION 6.44
- RVMD N/A
- 52 Week Low
- ZION $39.32
- RVMD $29.17
- 52 Week High
- ZION $63.22
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- ZION 78.42
- RVMD 47.77
- Support Level
- ZION $51.36
- RVMD $36.37
- Resistance Level
- ZION $56.57
- RVMD $38.97
- Average True Range (ATR)
- ZION 1.17
- RVMD 1.50
- MACD
- ZION 0.45
- RVMD 0.02
- Stochastic Oscillator
- ZION 97.59
- RVMD 40.07
About ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional US bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions focuses primarily on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.